Additionally, it is essential to consider the underlying reason for receiving L-Carnitine injections
Funding The author(s) declare that financial support was received for the research and/or publication of this article
( 3 ) In the SURMOUNT-4 trial, patients with obesity receiving tirzepatide had a mean 25.3% body weight loss over 88 weeks
External resources PubMed - Weight regain after GLP-1 RA interruption: narrative review eClinicalMedicine - Metabolic rebound after GLP-1 RA discontinuation: meta-analysis For researchers navigating the complexities of GLP-1 treatment duration, SeekPeptides provides comprehensive protocol guides, dosing calculators , and evidence-based resources designed to help you make informed decisions about your treatment timeline
Not every patient with excess weight is an appropriate candidate for GLP-1 therapy
B., Shetty, G., Ramesh, G